Mazor Robotics

Cordamed has been focused on the minimally invasive surgery (MIS) market since 2006, representing a new generation of medical device companies that have developed leading technology products.  Through its analytical experiences in biomedical engineering and a highly experienced post-sales assistance team, it has exclusive distribution rights for most of the robotic surgical systems that improve the quality of healthcare services standards in Turkey.

About Mazor
Mazor Robotics is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology.  For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com, the content of which does not form a part of this press release.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the the expansion of Mazor into key markets, the clinical and economic benefits of Renaissance, additional opportunities in Turkey, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements.  These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC), including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 filed with the SEC on and in subsequent filings with the SEC.  For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.


U.S. Contacts: EVC Group
Michael Polyviou/Robert Jones – Investors
mpolyviou@evcgroup.com; bjones@evcgroup.com
(212) 850-6020; (646) 201-5447

John Carter – Media
jcarter@evcgroup.com
(212) 850-6021

HomeRenaissance™PhysiciansAbout UsNewsInvestor Relationmazorrobotics.com/...-system-from-turkey-distribution-partner/

“Our momentum, both in the U.S. and internationally, and the purchase of these Renaissance systems demonstrates the continued support and interest which surgeons and hospital administrators express toward our technology,” commented Ori Hadomi, Chief Executive Officer. “We expect these hospitals to experience positive clinical and business benefits, similar to the other hospitals.”

About Mazor
Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the clinical and economic benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC), including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

U.S.:
EVC Group
Michael Polyviou/Robert Jones – Investors
212-850-6020; 646-201-5447
mpolyviou@evcgroup.com; bjones@evcgroup.com
John Carter – Media
212-850-6021
jcarter@evcgroup.com
mazorrobotics.com/...ers-in-the-u-s-and-international-markets/

2012
2012 Financial Statements 31 December 2012 (English)
2012 Annual Report 31 December 2012 (Hebrew)
Q3 2012 Interim Report 31 September 2012 (English)
Q3 2012 Interim Report 31 September 2012 (Hebrew)
Q2 2012 Interim Report 31 June 2012 (English)
Q2 2012 Interim Report 31 June 2012 (Hebrew)
Q1 2012 Interim Report 31 March 2012 (English)
Q1 2012 Interim Report 31 March 2012 (Hebrew)

2011
2011 Financial Statements 31 December 2011 (English)
2011 Annual Report 31 December 2011 (Hebrew)
Q3 Interim Report 30 September 2011 (English)
Q3 Interim Report 30 September 2011 (Hebrew)
Q2 Interim Report 30 June 2011 (Hebrew)
Q1 Fincancial Report 31 March 2011 (English)
Q1 Interim Report 31 March 2011 (Hebrew)

2010
2010 Annual Report 31 December 2010 (Hebrew)
2010 Annual Report 31 December 2010 (English)
Q3 Interim Report 30 September 2010 (Hebrew)
Q2 Interim Report 30 June 2010
(Hebrew)
Q1 Interim Report 31 March 2010 (Hebrew)

2009
2009 Annual Report 31 March 2009 (Hebrew)

Normal 0 false false false EN-US X-NONE HE MicrosoftInternetExplorer4 2011 Financial statementsmazorrobotics.com/investor-relations/financial-reports/

Closing Price (0.01 NIS)
3,802
Change(%) -3.75%
Turnover (NIS)
13,512,470
Trans.
1,506
Capital Listed for Trading
40,820,245
Market Cap (NIS thousands)
1,551,986
Base Price
3,950
Opening Price
3,850
High
3,850
Low
3,732
Yield MTD (%) 13.5%
Yield YTD (%) 13.5%
CUSIP 57886P202
Foreign Stock Exchange NASDAQ-CM
www.tase.co.il/eng/general/company/pages/...p;companyID=001487

reports on Mazor Robotics. Please note that this list is subject to change and that any estimates, forecasts, or opinions are made by the analysts alone and do not represent the estimates, forecasts, or opinions of Mazor Robotics or its management.
Jeffrey S. Cohen
Ladenburg Thalmann & Co. Inc.
Office: 305-572-4110
jcohen@ladenburg.com
Kathleen McGrath
WallachBeth Capital LLC
Office: 646-998-7607
kmcgrath@wallachbeth.com
Gregory Chodaczek
First Analysis Securities Corporation
(312) 258-7116
GChodaczek@firstanalysis.com
Jose T. Haresco III, Ph.D.
JMP Securities, LLC
(415) 869-4477
JHaresco@jmpsecurities.com
Matt Taylor
Barclays
(212) 526-6965
matthew.c.taylor@barclays.com
mazorrobotics.com/investor-relations/analyst-coverage/

  12.02.14     12,33     12,37§12,27 12,27 $ 1.470 17.535
  11.02.14    12,188     12,30§12,12 12,30 $ 3.883 45.975
  10.02.14     11,66     12,00§11,66 11,875 $ 971 10.636
  07.02.14     12,25     12,25§11,85 12,00 $ 1.400 16.684
  06.02.14    12,295    12,295§11,84 11,84 $ 1.866 15.845
  05.02.14     12,30     12,44§12,25 12,35 $ 1.490 17.293
  04.02.14     12,45     12,45§12,27 12,32 $ 6.037 74 T
  03.02.14     12,70     12,70§12,25 12,38 $ 5.690 70 T

GrB